Musculoskeletal and Skin Disorders - Page 1
Stay up to date with the latest Musculoskeletal and Skin Disorders updates from the global drugdevelopment industryLatest Musculoskeletal and Skin Disorders Update
Janssen Pharmaceuticals' Nucynta (tapentadol) extended-release (ER) tablets have been found effective in providing pain management among adults with chronic moderate to severe, painful...
> read more
Galapagos commences Phase 2a study of GLPG0634
Galapagos has begun the second Phase 2a clinical study of GLPG0634, a Janus kinase 1 (JAK1) inhibitor being developed to treat multiple autoimmune diseases, such as rheumatoid arthritis...
Auxilium announces Xiaflex data from Phase 2b study
Auxilium Pharmaceuticals has reported the results from the Phase 2b clinical trial of Xiaflex (collagenase clostridium histolyticum or CCH), used for the nonsurgical treatment of Peyronie's...
Zalicus concludes patient enrolment in rheumatoid arthritis trial
Zalicus has concluded patient enrolment in the Phase 2b trial of Synavive, a low-dose glucocorticoid, used for the treatment of patients with rheumatoid arthritis...
Repligen RG3039 drug found to treat neuromuscular disorder
Repligen has announced positive results from the Phase 1 study of RG3039, a small molecule drug candidate for the treatment of spinal muscular atrophy...
Summit wins MHRA approval to begin SMT C1100 Phase I study
UK-based drug discovery company Summit has received clearance from the Medicines and Healthcare products Regulatory Agency (MHRA) for its Phase I Clinical Trial Application (CTA) for SMT C1100...
PolyMedix PMX-30063 shows efficacy against staphylococcal infections
PolyMedix has announced the positive data from the Phase 2 proof-of-concept study investigating PMX-30063, a first-in-class investigational antibiotic, used for the treatment of Acute...
QRxPharma concludes MoxDuo CR Phase 1 studies on chronic pain
QRxPharma has completed two Phase 1 studies of MoxDuo controlled-release (CR), a dual-opioid formulation utilising a 3:2 ratio of morphine and...
UCB, Amgen begin Phase 3 study of osteoporosis drug
Belgium's UCB and Amgen have started the sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial programme for the treatment of postmenopausal...
Nektar doses first patients with NKTR-192 drug
Nektar Therapeutics has dosed the first subjects the Phase 1 clinical study of its NKTR-192 drug, designed for the treatment of moderate to severe acute...
Amgen reports Phase 2 study results of psoriasis drug
The Phase 2 trial of Amgen's Brodalumab (formerly AMG 827) drug has reported positive results in patients with moderate to severe plaque...
Provectus reports positive top-line data from randomised controlled psoriasis trial
Provectus Pharmaceuticals has reported positive top-line data for PH-10 in the randomised controlled trial (RCT) conducted in mild-to-moderate plaque psoriasis...
Galderma concludes Phase 3 studies of CD07805/47 gel
Galderma Laboratories has completed two independent Phase 3 clinical trials of CD07805/47, a topical gel under investigation in adults with moderate to severe facial erythema (redness) of...
VBL reports positive Phase 2 results of VB-201 drug
VBL Therapeutics' VB-201 drug has met the primary endpoint in a Phase 2 study, demonstrating a considerable reduction in vascular inflammation associated with atherosclerotic lesions in...
Abbott initiates Phase 3 studies of Humira drug
Abbott has begun two Phase 3 clinical trials to demonstrate the safety and efficacy of an investigational use of its Humira (adalimumab) drug in adult patients with moderate to severe...
Zelboraf oral therapy receives approval for UK market
The European Union Commission has licensed the use of Zelboraf (vemurafenib) in the UK to treat patients with BRAF V600 mutation positive unresectable or metastatic...
Basilea oral alitretinoin meets Phase III study endpoints
Switzerland-based Basilea Pharmaceutica's investigational compound Toctino (oral alitretinoin) has met study endpoints in its US Phase III HANDEL study in patients with severe chronic hand...
Actemra monotherapy found superior to adalimumab: Genentech reports
Genentech, a member of the Roche Group, has reported the preliminary results from its Adalimumab Actemra (ADACTA) study conducted in patients with rheumatoid arthritis (RA) who received...
Aastrom Biosciences begins Phase 3 study of Ixmyelocel-T
Aastrom Biosciences has initiated patient enrollment in the Revive Phase 3 clinical trial, designed to evaluate the efficacy and safety of Ixmyelocel-T in the treatment of patients with...
Critical Pharma, Nottingham University to jointly develop intranasal formulation for osteoporosis
Critical Pharmaceuticals has teamed up with the University of Nottingham to develop a nano-enabled intranasal formulation of teriparatide, intended for the treatment of...
Anacor reports safety and tolerability results of AN2728 ointment
Anacor Pharmaceuticals has reported positive preliminary results from two safety studies of AN2728 ointment,...
